Dr. Howard L. Kaufman is President and CEO of Ankyra Therapeutics in Boston. He has been a leading authority on tumor immunotherapy and oncolytic viruses for the treatment of melanoma. He led the first successful phase III trial of an oncolytic herpes virus that demonstrated clinical benefit in patients with melanoma, resulting in the first FDA approval of an oncolytic virus for the treatment of cancer. Dr. Kaufman earned his MD degree from Loyola University, completed a residency in General Surgery at Boston University and fellowship training at the National Cancer Institute. He has published over 500 peer-reviewed scientific papers, books, review articles, and abstracts.